'Get it done. We need it': Trump's coronavirus message to big pharma

3 March 2020 - President Donald Trump sought to show his personal engagement in the fight against coronavirus, meeting with ...

Read more →

Seqirus receives FDA approval for Fluad Quadrivalent (influenza vaccine, adjuvanted) for adults 65 years and older

24 February 2020 - Designed with MF59 adjuvant to help strengthen, broaden and lengthen the body's immune response against the influenza ...

Read more →

EMA to support development of vaccines and treatments for novel coronavirus

4 February 2020 - To contribute to the global response to the outbreak of the novel coronavirus (2019-nCoV) infections, EMA ...

Read more →

Seqirus announces U.S. FDA approval of its first-ever adjuvanted, cell-based pandemic influenza A (H5N1) vaccine

3 February 2020 - Seqirus, a global leader in influenza prevention and pandemic response, today announced that the U.S. FDA ...

Read more →

Emergent BioSolutions receives positive CHMP opinion for Vaxchora; anticipates near-term approval by European Medicines Agency

31 January 2020 - Emergent BioSolutions today announced that the CHMP of the EMA adopted a positive opinion for the approval ...

Read more →

Novavax granted fast track designation for NanoFlu in older adults

15 January 2020 - Novavax today announced that the U.S. FDA has granted fast track designation for NanoFlu, its recombinant quadrivalent ...

Read more →

Meissa Vaccines receives U.S. FDA fast track designation for respiratory syncytial virus vaccine, MV-012-968

10 January 2020 - Meissa Vaccines announced today that the U.S. FDA has granted fast track designation to MV-012-968, an ...

Read more →

PBAC – 2019 in review

8 January 2020 - The PBAC considered 188 submissions in 2019. ...

Read more →

Summary of submissions and outcomes from the November 2019 PBAC meeting

7 January 2020 - Analysis and insights from the November 2019 PBAC meeting. ...

Read more →

Meningococcal B vaccine rejected for inclusion on free schedule

22 December 2019 - It is the most common strain of deadly meningococcal disease, but the vaccine for the B strain ...

Read more →

First FDA approved vaccine for the prevention of Ebola virus disease, marking a critical milestone in public health preparedness and response

19 December 2019 - The U.S. FDA announced today the approval of Ervebo, the first FDA approved vaccine for the prevention ...

Read more →

Flawed forecasting? Why New Zealand ran out of MMR vaccine

16 December 2019 - PHARMAC's forecast for how many doses of MMR vaccine would be needed for 2019 was around ...

Read more →

Y-mAbs’ GD2-GD3 vaccine granted rare paediatric disease designation

12 December 2019 - Y-mAbs Therapeutics today announced that its GD2-GD3 vaccine has been granted a rare paediatric disease designation ...

Read more →

Seqirus announces Health Canada approval of first cell-based seasonal influenza vaccine

11 December 2019 - Seqirus, a global leader in influenza prevention, announced today that its cell-based quadrivalent influenza vaccine has ...

Read more →

2019-20 cost recovery implementation statement for PBS/NIP updated for 2018-19 financial outcome

12 December 2019 - The 2019–20 Cost Recovery Implementation Statement for the listing of medicines on the Pharmaceutical Benefits Scheme and ...

Read more →